• Pharming narrowed 2026 revenue guidance to US$ 380-390 million from US$ 375-395 million, implying 1-4% growth.
• Operating expense guidance fell by US$ 5 million to US$ 310-315 million.
• Third-quarter revenue rose 21% to US$ 117.6 million, supported by Joenja growth and RUCONEST’s return to growth.
• The outlook assumes accelerating Joenja growth, with RUCONEST revenue stabilizing and returning to growth in the second half.
• Available cash of US$ 190.9 million and future cash flows are expected to cover current pipeline and prelaunch costs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharming Group NV published the original content used to generate this news brief on October 27, 2026, and is solely responsible for the information contained therein.